(Reuters) - Latvian government health agencies on Tuesday announced a “temporary suspension” of up to two weeks of the use of AstraZeneca’s COVID-19 vaccine in the country.
The move is “an additional precaution” while the vaccine is scrutinized, and no problems have been linked to its use in Latvia, the agencies said in a statement.
“The decision is based on reports from individual European Union countries of thromboembolism and similar cases observed at various times after receiving the vaccine,” they said. “To date, there is no data on the causal link between vaccination and serious health problems.”
Germany, France and Italy said on Monday they would stop administering the AstraZeneca COVID-19 vaccine after several countries reported possible serious side-effects, while the World Health Organization said there was no proven link.
Reporting By Andrius Sytas; Editing by Catherine Evans
Our Standards: The Thomson Reuters Trust Principles.